Ibgliptin 20 Tablet contains Teneligliptin 20 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Teneligliptin enhances glycemic control by increasing the levels of incretin hormones, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, thereby improving postprandial and fasting blood glucose levels without causing significant hypoglycemia. This medication is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin when diet and exercise alone do not achieve adequate glycemic control. Ibgliptin 20 Tablet is well-tolerated and has a favorable safety profile, with minimal risk of weight gain or cardiovascular adverse effects. It is important to administer the tablet orally once daily, with or without food, as directed by a healthcare professional. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Patients should be advised to maintain lifestyle modifications including diet and physical activity to optimize therapeutic outcomes. Ibgliptin 20 Tablet should be used cautiously in patients with severe renal or hepatic impairment and is contraindicated in individuals with known hypersensitivity to Teneligliptin or any excipients.